Differential serum proteome profiling and electrochemical biosensing of leucine-rich alpha-2-glycoprotein (LRG1) and lipopolysaccharide-binding protein (LBP) as subtype-specific biomarkers for HPV-negative cervical cancer
PeerJ · 18.11.2026 · 14 · e21759
DOI: 10.7717/peerj.21759 ↗Kurz gefasst
Fachartikel in der Zeitschrift PeerJ, online erschienen am 18.11.2026. Verfasst von Kamolwan Watcharatanyatip und 10 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Thailand Science Research and Innovation, Chulabhorn Research Institute.
Abstract (Originalsprache)
Background
Cervical cancer (CC) is still a major global health concern. Specifically, human papillomavirus (HPV) - negative CC (HPV-neg CC) has a poorer prognosis than HPV-positive cases (HPV-pos CC). Distinguishing between HPV-pos and HPV-neg CC is the focus of this study, using proteomics and electrochemical biosensors.
Methods
Pooled serum samples from healthy individuals, HPV-pos CC, and HPV-neg CC patients were analyzed using label-free quantitative proteomics. Differentially expressed proteins (DEPs) were analyzed using PEAKS ® Studio software (≤1% False Discovery Rate, FDR; 1.5-fold change threshold). STRING and Metascape databases were used for protein-protein interaction analysis and functional clustering. An electrochemical impedance spectroscopy (EIS) biosensor was developed to quantify potential candidate biomarkers including lipopolysaccharide-binding protein (LBP) and leucine-rich alpha-2-glycoprotein (LRG1).
Results
Proteomics revealed distinct signatures, associating HPV-pos and HPV-neg CC with humoral immune response impairment and systemic inflammatory response, respectively. Concurrently, inflammatory mediators, LBP and LRG1 were top DEPs across all groups, with 3.99 and 2.89-fold increases in HPV-neg CC vs. healthy control, respectively. The EIS-based biosensor verified that LBP had remarkable discriminatory power in separating HPV-pos CC cases from HPV-neg CC cases (AUC = 0.9815), whereas LRG1 successfully separated cancer cases from healthy controls (AUC = 1.000).
Conclusions
Proteomics and EIS biosensor techniques identified LBP as a potential biomarker linked to systemic inflammatory responses in HPV-neg CC. Therefore, this pilot study links the gap between proteomic discovery and clinical application, eventually providing exploratory insights into subtype characterization for HPV-neg CC. Further investigations in a larger cohort based on our findings are necessary for a better understanding of the role of LBP and LRG1 in all CC subtypes.
Förderung
- Thailand Science Research and Innovation
- Chulabhorn Research Institute
Zitieren
APA
Watcharatanyatip, K., Chokchaichamnankit, D., Weeraphan, C., Chantaraamporn, J., Diskul-Na-Ayudthaya, P., Mekarunothai, A., Sritana, N., Kantathavorn, N., Svasti, J., Ruangjaroon, T., & Srisomsap, C. (2026). Differential serum proteome profiling and electrochemical biosensing of leucine-rich alpha-2-glycoprotein (LRG1) and lipopolysaccharide-binding protein (LBP) as subtype-specific biomarkers for HPV-negative cervical cancer. PeerJ, 14, e21759. https://doi.org/10.7717/peerj.21759
Vancouver
Watcharatanyatip K, Chokchaichamnankit D, Weeraphan C, Chantaraamporn J, Diskul-Na-Ayudthaya P, Mekarunothai A, et al. Differential serum proteome profiling and electrochemical biosensing of leucine-rich alpha-2-glycoprotein (LRG1) and lipopolysaccharide-binding protein (LBP) as subtype-specific biomarkers for HPV-negative cervical cancer. PeerJ. 2026;14:e21759. doi:10.7717/peerj.21759
BibTeX
@article{Watcharatanyatip2026,
author = {Watcharatanyatip, Kamolwan and Chokchaichamnankit, Daranee and Weeraphan, Churat and Chantaraamporn, Juthamard and Diskul-Na-Ayudthaya, Penchatr and Mekarunothai, Amita and Sritana, Narongrit and Kantathavorn, Nuttavut and Svasti, Jisnuson and Ruangjaroon, Theetat and Srisomsap, Chantragan},
title = {Differential serum proteome profiling and electrochemical biosensing of leucine-rich alpha-2-glycoprotein (LRG1) and lipopolysaccharide-binding protein (LBP) as subtype-specific biomarkers for HPV-negative cervical cancer},
journal = {PeerJ},
year = {2026},
volume = {14},
pages = {e21759},
doi = {10.7717/peerj.21759}
}
EUVIMED